Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

被引:63
作者
Odenike, Olatoyosi M. [1 ]
Alkan, Serhan [2 ]
Sher, Dorie
Godwin, John E. [2 ]
Huo, Dezheng
Brandt, Stephen J. [3 ]
Green, Margaret
Xie, Jingping [3 ]
Zhang, Yariming
Vesole, David H. [4 ]
Stiff, Patrick [2 ]
Wright, John [5 ]
Larson, Richard A.
Stock, Wendy
机构
[1] Univ Chicago, Med Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Loyola Univ, Maywood, IL 60153 USA
[3] Vanderbilt Univ, Nashville, IL USA
[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[5] NCI, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-08-1007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Recruitment of histone deacetylases (HDAC) is a mechanism of transcriptional repression implicated in the differentiation block in acute myeloid leukemia (AML). We hypothesized that the HDAC inhibitor romidepsin could cause transcriptional derepression, up-regulation of specific target genes in AML, and differentiation of the leukemic clone. The primary objectives of the study were to evaluate the safety and efficacy of romidepsin in advanced AML. Experimental Design: Twenty patients were stratified into cohort A or B based on the absence or presence of chromosomal abnormalities known to recruit HDACs, including those involving core binding factor (CBF). Romidepsin was administered i.v. at 13 mg/m(2)/d on days 1, 8, and 15 of a 28-day cycle. Pharmacodynamic endpoints were evaluated at serial time points. Results: Common adverse effects noted were grade 1 to 2 nausea, anorexia, and fatigue. No objective evidence of antileukemic activity was seen in cohort A. In cohort B, although there were no clinical responses by standard criteria, antileukemic activity was observed in 5 of 7 patients. Two patients had clearance of bone marrow blasts and 3 patients had a >50% decrease in bone marrow blasts. Furthermore, in cohort B, at 24 h, there was a significant increase in MDR1 (P = 0.005), p15 (P = 0.01), and p14 (P < 0.0001) expression. In cohort A, although there was a trend toward up-regulation of MDR1, p15, and p14 expression, these changes were not statistically significant. Conclusion: Romidepsin has differential antileukemic and molecular activity in CBF AML. Development of this agent in CBF AML should focus on combinations that target related mechanisms of gene silencing such as DNA methylation.
引用
收藏
页码:7095 / 7101
页数:7
相关论文
共 43 条
[1]   Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17) [J].
Amin, HM ;
Saeed, S ;
Alkan, S .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) :287-297
[2]   Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia [J].
Blum, William ;
Klisovic, Rebecca B. ;
Hackanson, Bjoern ;
Liu, Zhongfa ;
Liu, Shujun ;
Devine, Hollie ;
Vukosavljevic, Tamara ;
Huynh, Lenguyen ;
Lozanski, Gerard ;
Kefauver, Cheryl ;
Plass, Christoph ;
Devine, Steven M. ;
Heerema, Nyla A. ;
Murgo, Anthony ;
Chan, Kenneth K. ;
Grever, Michael R. ;
Byrd, John C. ;
Marcucci, Guido .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3884-3891
[3]   The translocation t(8;l6)(p11, p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB binding protein [J].
Borrow, J ;
Stanton, VP ;
Andresen, JM ;
Becher, R ;
Behm, FG ;
Chaganti, RSK ;
Civin, CI ;
Disteche, C ;
Dube, I ;
Frischauf, AM ;
Horsman, D ;
Mitelman, F ;
Volinia, S ;
Watmore, AE ;
Housman, DE .
NATURE GENETICS, 1996, 14 (01) :33-41
[4]   A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia [J].
Byrd, JC ;
Marcucci, G ;
Parthun, MR ;
Xiao, JJ ;
Klisovic, RB ;
Moran, M ;
Lin, TS ;
Liu, SJ ;
Sklenar, AR ;
Davis, ME ;
Lucas, DM ;
Fischer, B ;
Shank, R ;
Tejaswi, SL ;
Binkley, P ;
Wright, J ;
Chan, KK ;
Grever, MR .
BLOOD, 2005, 105 (03) :959-967
[5]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[6]   Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].
Cheson, BD ;
Bennett, JM ;
Kopecky, KJ ;
Büchner, T ;
Willman, CL ;
Estey, EH ;
Schiffer, CA ;
Döhner, H ;
Tallman, MS ;
Lister, TA ;
LoCocco, F ;
Willemze, R ;
Biondi, A ;
Hiddemann, W ;
Larson, RA ;
Löwenberg, B ;
Sanz, MA ;
Head, DR ;
Ohno, R ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649
[7]   Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228 [J].
Fecteau, KA ;
Mei, JX ;
Wang, HCR .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03) :890-899
[8]  
Ferrara FF, 2001, CANCER RES, V61, P2
[9]   Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes [J].
Garcia-Manero, Guillermo ;
Yang, Hui ;
Bueso-Ramos, Carlos ;
Ferrajoli, Alessandra ;
Cortes, Jorge ;
Wierda, William G. ;
Faderl, Stefan ;
Koller, Charles ;
Morris, Gail ;
Rosner, Gary ;
Loboda, Andrey ;
Fantin, Valeria R. ;
Randolph, Sophia S. ;
Hardwick, James S. ;
Reilly, John F. ;
Chen, Cong ;
Ricker, Justin L. ;
Secrist, J. Paul ;
Richon, Victoria M. ;
Frankel, Stanley R. ;
Kantarjian, Hagop M. .
BLOOD, 2008, 111 (03) :1060-1066
[10]   Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia [J].
Garcia-Manero, Guillermo ;
Kantarjian, Hagop M. ;
Sanchez-Gonzalez, Blanca ;
Yang, Hui ;
Rosner, Gary ;
Verstovsek, Srdan ;
Rytting, Michael ;
Wierda, William G. ;
Ravandi, Farhad ;
Koller, Charles ;
Xiao, Lianchun ;
Faderl, Stefan ;
Estrov, Zeev ;
Cortes, Jorge ;
O'Brien, Susan ;
Estey, Elihu ;
Bueso-Ramos, Carlos ;
Fiorentino, Jackie ;
Jabbour, Elias ;
Issa, Jean-Pierre .
BLOOD, 2006, 108 (10) :3271-3279